Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden.

Wang, Victoria E

Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden. [electronic resource] - Journal for immunotherapy of cancer 09 2017 - 75 p. digital

Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't

2051-1426

10.1186/s40425-017-0281-y doi


Antibodies, Monoclonal, Humanized--therapeutic use
Antineoplastic Agents, Immunological--therapeutic use
B7-H1 Antigen--genetics
Carcinoma, Neuroendocrine--drug therapy
Gene Amplification
Humans
Lung Neoplasms--drug therapy
Male
Middle Aged
Neoplasm Staging
Treatment Outcome
Tumor Burden